Methylone for the Treatment for PTSD: Initial Results From an Open-Label Study (IMPACT-1)

被引：0
|
作者：
Jones, Amanda [1 ]
Warner-Schmidt, Jennifer [1 ]
Stogniew, Martin [1 ]
Mandell, Blake [1 ]
Kwak, Hannah [1 ]
Miller, Paul W. [1 ]
Ching, Terence H. W. [1 ]
Averill, Lynnette [1 ]
Kelmendi, Benjamin [1 ]
机构：
[1] Transcend Therapeut, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
Methylone; PTSD; Transcend Therapeutics; Human; Clinical Trial;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P26
引用
收藏
页码：77 / 78
页数：2
相关论文
共 50 条
  • [21] Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease
    Melissa Toyos
    Rolando Toyos
    Barbara Jodoin
    Ryan Bunch
    Ophthalmology and Therapy, 2022, 11 : 1231 - 1240
  • [22] Results from a Prospective, Open-Label, Phase 4 Pilot Study of Repository Corticotropin Injection for Moderate and Severe Dry Eye Disease
    Toyos, Melissa
    Toyos, Rolando
    Jodoin, Barbara
    Bunch, Ryan
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (03) : 1231 - 1240
  • [23] Folinic acid as a treatment for autism in children: A within-subjects open-label study on safety and efficacy
    Wong, Chui Mae
    Tan, Charmain Samantha
    Koh, Hwan Cui
    Gan, Xinyi
    Hie, Szu Liang
    Saffari, Seyed Ehsan
    Yeo, Joo Guan
    Lam, Joyce Ching Mei
    INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 2025, 85 (01)
  • [24] Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study
    Feldt-Rasmussen, Ulla
    Hughes, Derralynn
    Sunder-Plassmann, Gere
    Shankar, Suma
    Nedd, Khan
    Olivotto, Iacopo
    Ortiz, Damara
    Ohashi, Toya
    Hamazaki, Takashi
    Skuban, Nina
    Yu, Julie
    Barth, Jay A.
    Nicholls, Kathleen
    MOLECULAR GENETICS AND METABOLISM, 2020, 131 (1-2) : 219 - 228
  • [25] Duloxetine and care management treatment of older adults with comorbid major depressive disorder and chronic low back pain: results of an open-label pilot study
    Karp, Jordan F.
    Weiner, Debra K.
    Dew, Mary A.
    Begley, Amy
    Miller, Mark D.
    Reynolds, Charles F., III
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 25 (06) : 633 - 642
  • [26] Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia
    Satlin, Andrew
    Vanover, Kimberly
    Durgam, Suresh
    Mates, Sharon
    Davis, Robert
    Correll, Christoph
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 493 - 494
  • [27] Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study
    Beck, Lisa A.
    Thaci, Diamant
    Deleuran, Mette
    de Bruin-Weller, Marjolein
    Chen, Zhen
    Khokhar, Faisal A.
    Zhang, Meng
    Ozturk, Zafer E.
    Shumel, Brad
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2022, 33 (03) : 1608 - 1616
  • [28] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Annunziata, Christina M.
    Kohn, Elise C.
    LoRusso, Patricia
    Houston, Nicole D.
    Coleman, Robert L.
    Buzoianu, Manuela
    Robbie, Gabriel
    Lechleider, Robert
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (01) : 77 - 84
  • [29] Drug-Drug Interaction Between Rifampicin and Albuvirtide: A Phase 1, Randomized, Open-Label Study
    Zhang, Li
    Chen, Jun
    Lin, Xiao-Yan
    Lu, Yan
    Wu, Yan
    Wu, Yi-Jun
    Meng, Xian-Min
    JOURNAL OF CLINICAL PHARMACOLOGY, 2025,
  • [30] Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
    Christina M. Annunziata
    Elise C. Kohn
    Patricia LoRusso
    Nicole D. Houston
    Robert L. Coleman
    Manuela Buzoianu
    Gabriel Robbie
    Robert Lechleider
    Investigational New Drugs, 2013, 31 : 77 - 84
12345